Bear Stearns puts Amgen at peer perform

Bear Stearns analyst Mark Schoenebaum gave Amgen Inc. a peer perform rating after the CERA hearing yielded no decision. At the worst, the case would be administratively closed, making it difficult to re-open at a later date. The analyst does not expect the case to be dismissed. Shares of the Thousand Oaks, Calif., biotechnology company were down $0.26 or 0.38%, at $67.28 on volume of 7,578,898 shares versus the three-month running average of 10,187,600 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.